alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT NO. 27

                                    CNS, INC.
               COMPUTATION OF NET INCOME PER SHARE OF COMMON STOCK


<TABLE>
<CAPTION>
                                             Three Months Ended          Nine Months Ended
                                                September 30,               September 30,
                                          -------------------------   -------------------------
                                             1997          1996          1997          1996
                                          -----------   -----------   -----------   -----------
<S>                                       <C>           <C>           <C>           <C>        
NET INCOME
   Net income                             $ 2,558,472   $ 3,894,417   $ 6,493,438   $10,042,825
                                          ===========   ===========   ===========   ===========

PRIMARY EARNINGS PER SHARE:
   Average number of common and common
   equivalent shares outstanding:
      Average common shares outstanding    19,274,000    19,145,000    19,244,000    18,556,000
      Incentive stock options                 395,000       635,000       461,000       646,000
      Non qualified stock options             232,000       391,000       271,000       402,000
      Warrants                                      0        75,000             0        76,000
                                          -----------   -----------   -----------   -----------
                                           19,901,000    20,246,000    19,976,000    19,680,000
                                          ===========   ===========   ===========   ===========

   Primary earnings per share             $       .13   $       .19   $       .33   $       .51
                                          ===========   ===========   ===========   ===========

FULLY DILUTED EARNINGS PER SHARE
   Average number of common and common
   equivalent shares outstanding:
      Average common shares outstanding    19,274,000    19,145,000    19,244,000    18,556,000
      Incentive stock options                 399,000       635,000       461,000       646,000
      Non qualified stock options             235,000       391,000       271,000       402,000
      Warrants                                      0        75,000             0        76,000
                                          -----------   -----------   -----------   -----------
                                           19,908,000    20,246,000    19,976,000    19,680,000
                                          ===========   ===========   ===========   ===========

   Fully diluted earnings per share       $       .13   $       .19   $       .33   $       .51
                                          ===========   ===========   ===========   ===========



</TABLE>
§ 522.930 Firocoxib. ( a ) *Specifications.* Each milliliter of solution contains 20 milligrams (mg) firocoxib.
( b ) *Sponsors.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 0.04 mg/pound (lb) (0.09 mg/kilogram (kg)) of body weight (BW) intravenously, once daily, for up to 5 days. If further treatment is needed, firocoxib oral paste can be administered at a dosage of 0.045 mg/lb (0.1 mg/kg) of BW for up to an additional 9 days of treatment.
( 2 ) *Indications for use.* For the control of pain and inflammation associated with osteoarthritis.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[75 FR 59611, Sept. 28, 2010, as amended at 84 FR 39184, Aug. 9, 2019]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7508 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
118th CONGRESS
  2d Session
                                H. R. 7508

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
   at 1285 Emancipation Highway in Fredericksburg, Virginia, as the 
                    ``Gladys P. Todd Post Office''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. GLADYS P. TODD POST OFFICE.

    (a) Designation.--The facility of the United States Postal Service 
located at 1285 Emancipation Highway in Fredericksburg, Virginia, shall 
be known and designated as the ``Gladys P. Todd Post Office''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Gladys P. 
Todd Post Office''.

            Passed the House of Representatives December 4, 2024.

            Attest:

                                                                 Clerk.
118th CONGRESS

  2d Session

                               H. R. 7508

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
   at 1285 Emancipation Highway in Fredericksburg, Virginia, as the 
                    ``Gladys P. Todd Post Office''.
```
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

IN RE: TERMINATION OF PARENTAL 

RIGHTS TO A.P.H., A MINOR

PETITION OF: S.L.L., MOTHER

:

:

:

:

:

No. 122 MAL 2022

Petition for Allowance of Appeal 

from the Order of the Superior Court

IN RE: TERMINATION OF PARENTAL 

RIGHTS TO M.S.H., A MINOR

PETITION OF: S.L.L., MOTHER

:

:

:

:

:

No. 123 MAL 2022

Petition for Allowance of Appeal 

from the Order of the Superior Court

IN RE: TERMINATION OF PARENTAL 

RIGHTS TO K.P.H., A MINOR

PETITION OF: S.L.L., MOTHER

:

:

:

:

:

No. 124 MAL 2022

Petition for Allowance of Appeal 

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 6th day of April, 2022, the Petition for Allowance of Appeal is 

DENIED.
Exhibit 32

# CERTIFICATION

The undersigned certify pursuant to 18 U.S.C. § 1350, that:

(1) The accompanying Quarterly Report on Form 10-Q for the period
ended December 31, 2003, fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and

(2) The information contained in the accompanying Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.

|Date: February 6, 2004 | By: /s/ Marti Morfitt                                  
|---------------------- | -------------------------------------------------------
|                       | Marti Morfitt                                          
|                       | President & Chief Executive Officer                    
|                      
|Date: February 6, 2004 | By: /s/ Samuel E. Reinkensmeyer                        
|                       | Samuel E. ReinkensmeyerVice President of Finance, Chief
|                       | Financial Officer and Treasurer                        

---
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3940 Total temporomandibular joint prosthesis. ( a ) *Identification.* A total temporomandibular joint prosthesis is a device that is intended to be implanted in the human jaw to replace the mandibular condyle and augment the glenoid fossa to functionally reconstruct the temporomandibular joint.
( b ) *Classification.* Class III.
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 30, 1999, for any total temporomandibular joint prosthesis that was in commercial distribution before May 28, 1976, or that has, on or before March 30, 1999, been found to be substantially equivalent to a total temporomandibular joint prosthesis that was in commercial distribution before May 28, 1976. Any other total temporomandibular joint prosthesis shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[59 FR 65478, Dec. 20, 1994, as amended at 63 FR 71746, Dec. 30, 1998]
RICHARD CHRISTINSEN

,

Appellant,

v.

STATE OF FLORIDA

,

Appellee

. IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO

FILE MOTION FOR REHEARING AND

DISPOSITION THEREOF IF FILED

CASE NO. 1D 16

- 0429

____ _________________________/

Opinion filed July 22, 2016.

An appeal from an order of the Circuit Court for Duval County

. Mallory D. Cooper , Judge

.

Nancy A. Daniels, Public Defender, and Steven L. Seliger, Assistant Public

Defender, Tallahassee , for Appell ant.

Pamela Jo Bondi, Attorney General, Tallahassee , for Appellee.

PER CURIAM.

AFFIRMED.

BILBREY

, KELSEY

, and M. K. THOMAS

, J J

. , CONCUR.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     (Replace this text with the legend)
</LEGEND>
<CIK>                         0000814458
<NAME>                        Healthcare Properties, L.P.
<MULTIPLIER>                  1
<CURRENCY>                    1.00
       
<S>                             <C>
<PERIOD-TYPE>                  6-MOS
<FISCAL-YEAR-END>              DEC-31-1997
<PERIOD-START>                 JAN-01-1997
<PERIOD-END>                   JUN-30-1997
<EXCHANGE-RATE>                1.00
<CASH>                         9,548,043
<SECURITIES>                   0
<RECEIVABLES>                  5,202,992
<ALLOWANCES>                   (4,255,655)
<INVENTORY>                    0
<CURRENT-ASSETS>               0
<PP&E>                         36,185,561
<DEPRECIATION>                 (14,716,452)
<TOTAL-ASSETS>                 32,483,454
<CURRENT-LIABILITIES>          0
<BONDS>                        0
<PREFERRED-MANDATORY>          0
<PREFERRED>                    0
<COMMON>                       0
<OTHER-SE>                     24,672,681
<TOTAL-LIABILITY-AND-EQUITY>   32,483,454
<SALES>                        0
<TOTAL-REVENUES>               4,816,903
<CGS>                          0
<TOTAL-COSTS>                  3,811,323
<OTHER-EXPENSES>               53,701
<LOSS-PROVISION>               0
<INTEREST-EXPENSE>             343,823
<INCOME-PRETAX>                608,056
<INCOME-TAX>                   0
<INCOME-CONTINUING>            0
<DISCONTINUED>                 0
<EXTRAORDINARY>                0
<CHANGES>                      0
<NET-INCOME>                   608,056
<EPS-PRIMARY>                  0
<EPS-DILUTED>                  0
        


</TABLE>
T hi s di s pos i t i on i s notappr opr i a t e f orpubl i c a t i on and i s notpr e c e de nt * e xc e pta s pr ovi de d by9th C i r . R . 36- 3.

T he pane lunani m ous l yc onc l ude s thi s c a s e i s s ui t abl e f orde c i s i on ** w ith o u t o r a l ar g u m e n t. See F ed. R . A pp . P . 34 (a )( 2). NOT F OR P UB L I CAT I ON UN I TE D STATE S C OU RT OF APPE ALS FOR T HE NI NTH CI RC UI T R AF AE L P E R E Z - AY AL A, P et i t i on er , v. E R I C H . H O L D E R , J r ., A tto rn e yG e n e r a l, R e s p o n d e n t. N o. 09- 70026 A ge nc yN o. A 075- 765- 068 ME MOR AN DU M *

O n P e t i t i on f

orR e vi e w of

an O r de rof

the B o ar do f I m m ig r a tio n A p p e a ls S ubm i tt e d Jul y12, 2011 ** B e f o r e : S C H R O E D E R , A L A R C Ó N , an dL E A V Y , C ir c u it Ju d g e s . R a f a e lP e r e z - A y a l a , ana t i ve and c i t i z e n of M e xi c o, pe t i t i ons pr o s e f or r e v ie w o f

th e B o ar do f

I m m ig r a tio n A p p e a ls ’ ( “B I A ” ) o r d e rd e n y in g h is m o tio n to re op en base d o n i neff

ec t i ve as si st ance of coun se l . W e have j uri sdi ct i on un der 

# FI LED JU L 21 2011 M OLLY C. DW Y ER, CLERK U . S. C O U R T OF APPE ALS09- 70026 2 8 U .S .C . § 1 2 5 2 . W e r e v ie w f o rab u s e o f

d is c r e tio n th e d e n ia l o f am o tio n to r e o p e n . Moh am m ed v. G on zales , 400 F . 3d 785, 791- 92 ( 9th C i r . 2005) . W e de ny th e p e titio n f

o rr e v ie w . T h e B I A d idn o t ab u s e its d is c r e tio n in d e n y in g P e r e z - A y a la ’s m o tio n to r e ope n be c aus e i tw a s f i l e d a l m os tf

i ve y e ar s a f

t e rthe B I A ’ s O c t obe r23, 2003, o r d e r , se e 8 C . F . R . § 1003. 2( c ) ( 2) , and P e r e z - A y a l af a i l e d t o de m ons tr a t e tha the a c te dw ith th e du e d ilig e n c e r e qu ir e df o re qu itab le to llin g , se e I tu rr i b a rr i a v . I

NS , 3 2 1 F .3 d8 8 9 , 8 9 9 ( 9 th C ir . 2 0 0 3 ) ( e qu itab le to llin g av a ilab le w h e r e “ap e titio n e ris prevent ed fr om fi l i ng because of dec ept i on , fr aud, or error, as l on g as the pet i t i on er ac t s w i th due di l i gence”) . P E T I T I O N F O R R E V I E W D E N I E D .
§ 80.39 Records of distribution. ( a ) The person to whom a certificate is issued shall keep complete records showing the disposal of all the color additive from the batch covered by such certificate. Upon the request of any officer or employee of the Food and Drug Administration or of any other officer or employee acting on behalf of the Secretary of Health and Human Services, such person, at all reasonable hours until at least 2 years after disposal of all such color additive, shall make such records available to any such officer or employee, and shall accord to such officer or employee full opportunity to make inventory of stocks of such color additive on hand and otherwise to check the correctness of such records.
( b ) The records required to be kept by paragraph (a) of this section shall show: ( 1 ) Each quantity used by such person from such batch and the date and kind of such use.
( 2 ) The date and quantity of each shipment or delivery from such batch, and the name and post-office address of the person to whom such shipment or delivery was made.
( c ) The records required to be kept by paragraph (a) of this section shall be kept separately from all other records.
#### Stanley Pawlowski et al. *v.*Planning and Zoning Commission of the Town of Ellington et al.

King, C. J., Alcorn, House, Cotter and Thim, Js.

Argued November 13

decided December 17, 1968

*Phillip E. Tatoicm, Jr.,*with whom, on the brief, was *Phillip E. Tatoicm,*for the appellants (plaintiffs).

*Jerome I. Walsh,*for the appellee (named defendant).

*Etalo G. Gvmtti,*for the appellees (defendant Sweet et al.).

Per Curiam.

The planning and zoning commission of the town of Ellington granted a special exception for the establishment of a sanitary landfill disposal operation on a twenty-seven-acre tract of land in an industrial zone. The plaintiffs, who own property in the area, have appealed from a judgment of the Court of Common Pleas dismissing their appeal.

On the present appeal, the plaintiffs seek to correct the finding by requesting the inclusion of certain paragraphs of the draft finding which they *599claim are undisputed. The plaintiffs, however, cannot succeed in this attempt because of their failure to include in the appendix to their brief anything which shows that the facts sought to be included were admitted or undisputed within the rule of cases such as *Brown*v. *Connecticut Light & Power Co.,*145 Conn. 290, 293, 141 A.2d 634.

The plaintiffs claim that the trial court committed error by concluding that they were not aggrieved persons. The decisive issue on this appeal is whether the facts recited in the limited finding compelled the conclusion that the plaintiffs were aggrieved.

It would serve no useful purpose to recount the relevant facts. It is sufficient to note that the finding reasonably supports the conclusion of the trial court that the plaintiffs were not aggrieved, and that conclusion should not be disturbed by us. See *Josephson*v. *Planning Board,*151 Conn. 489, 492, 199 A.2d 690; *London*v. *Planning & Zoning Commission,*149 Conn. 282, 284, 179 A.2d 614.

There is no error.
#### Julia DeLucco et al. *v.*Mott’s Super Markets, Inc.

King, C. J., Alcorn, House, Thim and Ryan, Js.

Argued June 3

decided June 17, 1969

*616
      *Gerald B. Swirsky,*for the appellant (defendant).

*Robert B. Cohen,*for the appellees (plaintiffs).

Per Curiam.

The question of negligence on the part of the defendant and the question of contributory negligence on the part of the named plaintiff presented factual issues for the jury to determine. The verdict was a result which could reasonably have been reached on a permissible view of the evidence. *Bonomo*v. *Capitol City Lumber Co.,*154 Conn. 714, 228 A.2d 501. The court, therefore, did not err in refusing to set it aside. *Hemmings*v. *Weinstein,*151 Conn. 502, 505, 199 A.2d 687.

There is no error.
****EXHIBIT 32****

CERTIFICATE OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of GVC Venture Corp. (the “Company”) on Form 10-Q for the quarter ended December 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard Zimmerman, Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002        that, to the best of my knowledge:

|   | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

 

 

| February 6, 2009 | /s/ Bernard Zimmerman                                                             |
|------------------|----------------------------------------------------------------------------------------|
|             | Bernard Zimmerman, President                                                           |
|             | (Principal Executive Officer) andTreasurer (Principal Financial andAccounting Officer) |
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of MBIA Inc. (the Company) on Form 10-Q for the period ending
June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Joseph W. Brown, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                       
|-----------------------
|/s/ Joseph W. Brown    
|Joseph W. Brown        
|Chief Executive Officer
|August 6, 2009
Court of Appeals

of the State of Georgia

ATLANTA,____________________

The Court of Appeals hereby passes the following order:

A18A2156. TONY L. WARE v. PINE STATE MORTGAGE CORPORATION

et al.

In this civil action, plaintiff Tony L. Ware has filed a direct appeal of the trial

court’s order recusing, sua sponte, the assigned trial court judge. We lack

jurisdiction.

Because this action remains pending below, the plaintiff was required to use

the interlocutory appeal procedures – including obtaining a certificate of immediate

review from the trial court – to appeal. See OCGA § 5-6-34 (b); Boyd v. State, 191

Ga. App. 435 (383 SE2d 906) (1989). “[A] party wishing to appeal a pretrial ruling

on a recusal motion has the option to seek an interlocutory appeal or to appeal

immediately after an adverse final judgment.” Murphy v. Murphy, 295 Ga. 376, 379

n.3 (761 SE2d 53) (2014);see also Evans v. Williams, 341 Ga. App. 226, 228-229 (2)

(799 SE2d 362) (2017) (if a motion to recuse is granted, a party may file an

application for interlocutory review of the recusal order, or choose to continue the

case under the direction of the newly appointed judge). Further, a recusal ruling is

not subject to the collateral order doctrine. See Murphy v. Murphy, 322 Ga. App.

829, 832 (747 SE2d 21) (2013). 

August 22, 2018
Accordingly, this appeal is hereby DISMISSED. 

Court of Appeals of the State of Georgia

Clerk’s Office, Atlanta,____________________

I certify that the above is a true extract from

the minutes of the Court of Appeals of Georgia.

Witness my signature and the seal of said court

hereto affixed the day and year last above written.

, Clerk.

08/22/2018
```

[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10313]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4771]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances Notice of Registration

    By Notice dated October 21, 2009, and published in the Federal 
Register on October 28, 2009 (74 FR 55584), Cerilliant Corporation, 811 
Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application 
via the Internet to the Drug Enforcement Administration (DEA) to be 
registered as an importer of 5-Methoxy-N,N-diisopropyltryptamine 
(7439), a basic class of controlled substance listed in schedule I.
    The company plans to import small quantities of the listed 
controlled substance for the manufacture of analytical reference 
standards.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and Sec.  952(a), and determined that 
the registration of Cerilliant Corporation to import the basic class of 
controlled substance is consistent with the public interest, and with 
United States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971, at this time. DEA has investigated 
Cerilliant Corporation to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, 
the above named company is granted registration as an importer of the 
basic class of controlled substance listed.

     Dated: February 26, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-4771 Filed 3-4-10; 8:45 am]
BILLING CODE 4410-09-P
```
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2350 Electrocardiograph lead switching adaptor. ( a ) *Identification.* An electrocardiograph lead switching adaptor is a passive switching device to which electrocardiograph limb and chest leads may be attached. This device is used to connect various combinations of limb and chest leads to the output terminals in order to create standard lead combinations such as leads I, II, and III.
( b ) *Classification.* Class II (performance standards).